Tags: Cancer | blood | cancer | Pomalyst | multiple | myeloma | drug

New Lifesaving Blood Cancer Drug OKd

Thursday, 07 Mar 2013 09:27 AM

Pomalyst (pomalidomide) has been approved by the FDA to treat cases of multiple myeloma that have not responded to other therapies.

The disease, a form of blood cancer, affects some 21,700 Americans annually and nearly 10,700 die from it each year, the agency said Friday in a news release.

Pomalyst is designed to spur the immune system to destroy and inhibit cancer cells, the FDA said. The drug's safety and effectiveness were evaluated in a clinical study of 221 people with advanced multiple myeloma.

Obamacare
: Massive New Rules Revealed for 2013

The drug's label will contain a boxed warning that it shouldn't be used by pregnant women since it can cause life-threatening birth defects and blood clots, the FDA said.

More common side effects could include a drop in infection-fighting white blood cells, fatigue, weakness, other blood disorders, back pain and fever.

The drug is marketed by Celgene, based in Summit, N.J.

© HealthDay

1Like our page
2Share
FDA-Approved-Drugs
Pomalyst (pomalidomide) has been approved by the FDA to treat cases of multiple myeloma that have not responded to other therapies. The disease, a form of blood cancer, affects some 21,700 Americans annually and nearly 10,700 die from it each year, the agency said Friday in...
blood,cancer,Pomalyst,multiple,myeloma,drug
153
2013-27-07
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved